Mifepristone (RU486) is a born‐for‐woman molecule discovered three decades ago. Unlike
those antihypertensive and antipsychotic pharmaceutical blockbusters, this abortifacient …

Introduction Patients with various advanced cancers devoid of nuclear progesterone
receptors (nPR) have demonstrated increased quality and length of life when treated with …

Chemoresistance is a major unmet clinical obstacle in ovarian cancer treatment. Epigenetics
plays a pivotal role in regulating the malignant phenotype, and has the potential in …

Antiprogestins constitute a group of compounds, developed since the early 1980s, that bind
progesterone receptors with different affinities. The first clinical uses for antiprogestins were …

Background Mifepristone (MF) has been largely used in reproductive medicine due to its
capacity to modulate the progesterone receptor (PR). The study of MF has been expanded …

Background Recent clinical trials on ovarian cancer with mifepristone (MF) have failed,
despite in vitro findings on its strong progesterone (P4) antagonist function. Methods …

According to a Prognoscan database, upregulation of Bruton's tyrosine kinase (Btk) is
associated with low overall survival in ovarian cancer patients. We found that spheroids …

Background Changes in cell shape and plasticity in cytoskeletal dynamics are critically
involved in cell adhesion, migration, invasion and the overall process of metastasis …

Background Advanced ovarian cancer is treated with cytoreductive surgery and combination
platinum-and taxane-based chemotherapy. Although most patients have acute clinical …

Progesterone induced blocking factor (PIBF) is a unique protein that is not present in normal
cells, but is found predominantly in rapidly growing cells of the fetal placental unit or cancer …